Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (1090)	7/23/1999 12:14:00 AM
From: JEB	Respond to of 1686

go2net.newsalert.com Beck on Bio Tech Announces Investment Opinion Business Wire - July 21, 1999 17:18 "Biopharmaceutical Industry Exhibiting Strength, Consolidation Continues" according to the Beck On Bio Tech newsletter Following years of lackluster performance, the biopharmaceutical sector bounced back significantly in 1999, according to Michael D. Becker, Editor of the monthly "Beck On Bio Tech" newsletter. Year-to-date (through 07/13/99), the NASDAQ Biotech Index gained a healthy 26.54% while the AMEX Biotech Index recorded an impressive 25.37% increase. Both indices handily beat the S&P 500 Index, which advanced 13.37% during the same period. Large capitalization issues, such as Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BGEN) and Genzyme (NASDAQ:GENZ), reached new all-time highs during the first half of 1999. Merger and acquisition speculation helped the performance of selected smaller capitalization companies, with Pharmacia & Upjohn (NYSE:PNU) announcing a definitive pact to acquire Sugen (NASDAQ:SUGN), Gilead Sciences (NASDAQ:GILD) buying NeXstar Pharmaceuticals (NASDAQ:NXTR) and Warner-Lambert (NYSE:WLA) purchasing Agouron Pharmaceuticals (NASDAQ:AGPH). Continuing this trend, today Johnson & Johnson (NYSE:JNJ) made an offer to buy Centocor (NASDAQ:CNTO). "Since many smaller capitalization biopharmaceutical companies are trading at depressed levels during a period where larger capitalization biotechs and major pharmaceutical companies are flush with cash, the trend towards consolidation could continue," said Becker. Celebrating the anniversary of its first year, the "Beck On Bio Tech" monthly newsletter enumerates many different aspects of the biotechnology/pharmaceutical sector. In addition, many issues feature a "company spotlight" that details individual companies who offer unique value or technology. Recently spotlighted companies include Liposome (NASDAQ:LIPO), Cephalon (NASDAQ:CEPH), Affymetrix (NASDAQ:AFFX), and Myriad Genetics (NASDAQ:MYGN). The July issue highlights the performance of each "spotlighted" company since the inception of the newsletter. For information on how to receive "Beck On Bio Tech" monthly, contact Michael Becker at 312/431-1700, or via email at mbecker@whummer.com In addition, web site: www.whummer.com/newenhanced/biotech/home.html Disclaimers - Michael Becker is an investment executive/analyst with Wayne Hummer Investments LLC. All comments and opinions are solely those of Michael Becker and are not in any way comments or opinions of Wayne Hummer Investments LLC. Additional information is available upon request. Information in this release has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The opinions and information presented do not constitute a solicitation for the purchase or sale of any securities or options on securities. The security portfolio of our employees, clients, principals or affiliated companies may, in some instances, include securities and/or options on securities mentioned in this issue.